863015-82-1 Usage
General Description
[1,3,4]OXATHIAZINANE 3,3-DIOXIDE is a chemical compound with the molecular formula C3H5NO2S. It is a heterocyclic compound containing a six-membered ring with oxygen and sulfur atoms. This chemical is commonly used as a building block in the synthesis of various pharmaceuticals and agricultural products. It has also been studied for its potential biological activities, including its role as an anti-inflammatory and anti-cancer agent. Additionally, [1,3,4]OXATHIAZINANE 3,3-DIOXIDE has been investigated for its potential use as a catalyst in chemical reactions. Due to its unique structure and potential applications, this compound is of interest to researchers in the fields of chemistry, medicine, and materials science.
Check Digit Verification of cas no
The CAS Registry Mumber 863015-82-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,3,0,1 and 5 respectively; the second part has 2 digits, 8 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 863015-82:
(8*8)+(7*6)+(6*3)+(5*0)+(4*1)+(3*5)+(2*8)+(1*2)=161
161 % 10 = 1
So 863015-82-1 is a valid CAS Registry Number.
863015-82-1Relevant articles and documents
6,7-DIHYDRO-4H-PYRAZOLO[1,5-A]PYRAZINE AND 6,7-DIHYDRO-4H-TRIAZOLO[1,5-A]PYRAZINE COMPOUNDS FOR THE TREATMENT OF INFECTIOUS DISEASES
-
Page/Page column 36; 37, (2018/03/28)
The present invention relates to compounds of the formula (I), or pharmaceutically acceptable salts, enantiomer or diastereomer thereof, wherein R1 to R4 and Q are as described above. The compounds may be useful for the treatment or prophylaxis of hepatitis B virus infection.
CYCLIC SULFONAMIDE CONTAINING DERIVATIVES AS INHIBITORS OF HEDGEHOG SIGNALING PATHWAY
-
Paragraph 0239, (2014/05/24)
The invention relates generally to the creation and use of cyclic sulfonamide containing derivatives to inhibit the hedgehog signaling pathway and to the use of those compounds for the treatment of hyperproliferative diseases and angiogenesis mediated diseases.
